InMed-logo-01
Subscribe
NASDAQ_Logo

Press Releases

Press Releases

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
InMed to Participate in Upcoming Investor Conferences in April and May 2022
InMed Announces Management Changes
InMed to Present at the 34th Annual Roth Conference
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022
Displaying 1 - 10 of 203
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

Pharmaceutical

Investor

Products

About

Learn

© Copyright 2022 InMed Pharmaceuticals Inc.